Loading...
•
Dec 31, 2021
Bio-Techne Q2 2022 Earnings Report
Bio-Techne's Q2 2022 earnings showcased strong growth, driven by operational excellence and strategic investments.
Key Takeaways
Bio-Techne reported a strong second quarter in fiscal year 2022, with a 20% increase in net sales to $269.3 million and organic revenue growth of 17%. The company's adjusted EPS increased to $1.88, and adjusted operating income rose by 18% to $102.8 million. The Protein Sciences segment demonstrated sustained operational excellence, achieving 19% organic growth.
Second quarter organic revenue increased by 17% (20% reported) to $269.3 million.
GAAP EPS was $1.94 versus $1.15 one year ago.
Adjusted EPS increased to $1.88 per diluted share, versus $1.62 in the same quarter last year.
Adjusted operating income for the second quarter of fiscal 2022 increased 18% compared to the second quarter of fiscal 2021.
Revenue by Segment
Forward Guidance
The Wilson Wolf future investment and acquisition agreement signed in December has the potential to further extend the company's 2026 revenue target beyond $2 billion and positions its Cell and Gene Therapy workflow with the strongest global footprint in this exploding new market.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...